Objectives Tamoxifen bioactivation to endoxifen is mediated primarily by CYP2D6; however, considerable variability remains unexplained. Our aim was to perform a comprehensive assessment of the effect of genetic variation in tamoxifen-relevant enzymes and transporters on steady-state endoxifen concentrations.
Introduction
Tamoxifen, a selective estrogen receptor modulator, is used to prevent the recurrence of estrogen receptorpositive (ER + ) breast cancer in the adjuvant treatment of premenopausal and postmenopausal women, as well as for the treatment of metastatic disease and ductal carcinoma in situ [1] . Tamoxifen is metabolized into several metabolites with greater antiestrogenic potency including 4-hydroxy-tamoxifen and endoxifen [2] . Reaching therapeutic concentrations of these metabolites, particularly endoxifen, may be critical to the efficacy of tamoxifen treatment; patients above a therapeutic threshold have been reported to have lower recurrence rates than women with lower concentrations [3, 4] .
The enzyme primarily responsible for metabolic conversion of tamoxifen into endoxifen is CYP2D6, but other enzymes and transporters are also active in this metabolic pathway [5] . Genetic variation in CYP2D6 has a profound effect on endoxifen serum concentrations as it is the main pathway for the conversion of the primary tamoxifen metabolite, N-desmethyltamoxifen, into endoxifen, and considerably contributes toward the formation of 4-OH tamoxifen from tamoxifen [3, 6] . Patients with genotypes that confer the CYP2D6 poor metabolizer (PM) phenotype have lower endoxifen concentrations than those with intermediate (IM), normal [NM, formerly referred to as extensive (EM)], or ultra-rapid (UM) metabolizer status [7] .
Besides CYP2D6, there are several enzymes and transporters that are known to play a role in the metabolism and/or the distribution of tamoxifen and endoxifen.
Previous studies have reported associations between
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tamoxifen and/or its metabolites for common functionally consequential single nucleotide polymorphisms (SNPs) in CYP2C9 [4, 5, 8] and CYP2C19 [4, 8, 9] . In addition to genetics, there are some patient-specific factors such as height, weight, and the calendar date that may contribute toward steady-state endoxifen concentrations [10] . It may be possible to use genetic and clinical information to predict a patient's endoxifen concentration before initiation and use this information to guide personalized tamoxifen dose adjustment to achieve therapeutic endoxifen concentrations. Several groups, including ours, have piloted this approach by dose escalating patients with low-activity CYP2D6 genotypes and have made progress toward normalizing endoxifen concentrations without increasing treatment-related toxicity [2, [11] [12] [13] [14] . In addition, one study dose escalated patients solely on the basis of baseline endoxifen [15] ; however, these studies could not achieve comparable endoxifen levels in CYP2D6 PM patients, suggesting that other genetic data and clinical variables need to be incorporated into a prediction algorithm.
Further research is needed to determine the impact of SNPs in enzymes and transporters on endoxifen concentrations to improve the accuracy of personalized tamoxifen dosing algorithms. Previous pharmacogenetic studies have used a candidate SNP approach with limited allelic coverage. Our aim was to use a comprehensive genotyping approach that includes the vast majority of functionally consequential SNPs in the genes relevant to endoxifen pharmacokinetics (CYP2C9, CYP2C19, CYP3A4, CYP3A5) [4, 5, 8, 9, [16] [17] [18] [19] [20] to discover genetic predictors of steady-state endoxifen concentrations in patients receiving tamoxifen treatment. We also included additional enzymes and transporters that have insufficient available information to rule out their involvement in endoxifen concentrations, several of which have been associated previously with tamoxifen efficacy and/or toxicity [21] [22] [23] .
Patients and methods

Patient cohort
Patients included in this secondary analysis were originally enrolled in a prospective clinical study of CYP2D6 genotype-guided tamoxifen dose escalation (UNC Lineberger Comprehensive Cancer Center 0801) [2] . Detailed inclusion and exclusion criteria have been reported previously, but briefly, women 18 years of age and older and taking tamoxifen 20 mg for at least 4 months before study entry were eligible for enrollment unless they had Eastern Cooperative Oncology Group performance status above 2, impaired liver, bone marrow or kidney function, history of thromboembolic disease, previous liver or bone marrow transplant, had received blood transfusions within 3 months of study entry, or were taking strong CYP2D6 inhibitors. Patients taking medications known to inhibit CYP2D6 including amiodarone, bupropion, cimetidine, haloperidol, indinavir, ritonavir, terbinafine, quinidine, duloxetine, paroxetine, or fluoxetine were excluded. Those taking weak inhibitors of CYP2D6 (venlafaxine, citalopram, sertraline, or escitalopram) were included. After an initial pilot study of 120 patients [2] , the study was expanded to include a total of 500 participants [24] .
Sample and data collection
Patient demographic and treatment information including age, weight, menopausal status, self-reported race, duration of tamoxifen therapy, and concomitant medication was collected at study entry. Genomic DNA was isolated from the blood samples collected at entry into the clinical trial for germline genotyping. Baseline tamoxifen and metabolite concentrations were measured at baseline when all patients were taking tamoxifen 20 mg daily and had reached steady state. The following metabolites were measured in addition to tamoxifen: 4-OH tamoxifen, N-desmethyltamoxifen, and endoxifen. Concentrations were determined by liquid chromatography-mass spectrometry by collaborators at Indiana University using a previously described assay [2] .
Genotyping and activity phenotype prediction
At study enrollment, CYP2D6 status was determined for each participant using the Roche AmpliChip CYP450 Test (Indianapolis, Indiana, USA). Genotype was categorized into diplotypes (i.e. NM/IM, NM/PM, IM/IM, IM/PM) and then phenotypes (UM, NM, IM, PM) as described previously [25] . Phenotypes UM and NM were combined because of small numbers of UM phenotypes and previous work in the cohort that confirmed that differences in activity are negligible [25] . Residual DNA samples were genotyped for 36 additional genes, primarily CYP450 enzymes and drug transporters, on the iPLEX ADME PGx Pro Panel by Agena Bioscience (San Diego, California, USA) for this secondary pharmacogenetic analysis. All genetic information was subjected to appropriate quality control. SNPs with genotyping call rate below 95% and samples with a call rate of less than 90% across all genotyped SNPs were excluded from analysis. Of the 36 genes genotyped on the panel, the following 19 genes were chosen to be included in the analysis on the basis of their potential contribution toward tamoxifen metabolism or transport: CYP2C9, CYP3A4, CYP3A5, ABCB1, SLOCO1B1, SULT1A1, SULT1A2, UGT2B7, UGT2B15, UGT2B17, CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C19, CYP2C8, CYP2E1, ABCC2, and ABCG2. Each allele was assigned a predicted activity determination (low, normal, and high) on the basis of published data and each patient's activity diplotype was translated into predicted activity phenotypes (poor, intermediate, normal, or ultra-rapid) for analysis as described in Supplementary Tables 1 and 2 (Supplemental digital content, http://links.lww.com/FPC/ B270).
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Statistical analysis
Patients who were genotyped successfully and had baseline endoxifen concentration data measured on the modified assay used for the expansion cohort were included in the analysis. Steady-state endoxifen concentrations were subjected to square root transformation to improve distributional normality. Predicted activity for each enzyme or transporter was analyzed assuming an additive effect, with the number of levels (3 or 4) corresponding to the number of phenotypes described in Supplementary Table 2 (Supplemental digital content, http://links.lww.com/FPC/B270). Clinical variables analyzed included age and weight as continuous variables, season of sample collection (January-March, April-June, July-September, October-December), CYP2D6 inhibitor status (none or weak CYP2D6 inhibitor), menopausal status (premenopausal or postmenopausal), and self-reported ethnicity (White, African-American, or other) as categorical variables. Associations between predicted activity phenotype or clinical variables and baseline steady-state concentration for tamoxifen and its metabolites were analyzed using univariate linear regression. Following univariate analysis, genetic associations were adjusted for clinical covariates that were significant in the univariate setting. Multivariable models were constructed with each combination of CYP2C8, CYP2C9, and CYP2C19 activity phenotypes to assess the independent contribution of each gene. The most parsimonious model was selected on the basis of Akaike Information Criterion (AIC) and R 2 values were estimated from the linear regression models. As a hypothesis-generating secondary screen, the association of each predicted activity phenotype with tamoxifen, its other metabolites (4-OH tamoxifen and N-desmethyltamoxifen), and their metabolic ratios was evaluated. An uncorrected P value threshold of less than 0.05 was considered statistically significant for all analyses, which were carried out in SAS v9.4 statistical software (Cary, North Carolina, USA).
Results
Patient and demographic data
After excluding patients with missing endoxifen concentration or genetic data, 302 patients were included in the final analysis (Fig. 1 ). Patient demographic data including age, weight, race, date of sample collection, CYP2D6 diplotype, and concomitant use of a CYP2D6 inhibitor (i.e. citalopram, escitalopram, sertraline, or venlafaxine) are shown in Table 1 . The average age in this cohort was 52.8 years, 85% of the patients selfreported as Caucasian, and 45% were premenopausal. The CYP2D6 phenotype distribution was similar to that reported previously in this cohort, with 37% having the NM phenotype (NM/NM diplotype), 4% having the PM phenotype (PM/PM diplotype), and the remaining~60% having the IM phenotype, which can be subdivided into several diplotypes as reported in Table 1 [25] .
Univariate associations of clinical and genetic data
In the univariate analysis, an increase in the steady-state endoxifen concentration was detected for patients with increased CYP2C9 phenotype activity [linear regression CONSORT diagram of patient matriculation from clinical trial to this pharmacogenetic analysis. Of the 500 patients enrolled in the original clinical trial, 361 had evaluable endoxifen data, 355 had usable CYP2D6 genetic information, and 302 were genotyped successfully on the ADME PGx Pro Panel and were included in this analysis.
β coefficient = 0.20, 95% confidence interval (CI): 0.01-0.39, P = 0.04] and CYP2C8 phenotype activity (β = 0.22, 95% CI: 0.03-0.40, P = 0.02, Table 2 and Fig. 2 ). None of the other genes analyzed were associated with endoxifen concentration in the univariate analysis, although there was a suggestive trend for SLCO1B1 (P = 0.07, Table 2 ) and CYP2C19 (P = 0.11, Table 2 and Fig. 2) .
A significant association was found, with higher weight associated with lower endoxifen concentration (β = − 0.014, 95% CI: − 0.020 to − 0.008, P < 0.0001, Fig. 3 ). We also found that patients whose samples were collected in the fall (β = − 0.55, 95% CI: − 0.84 to − 0.26, P = 0.0002), summer (β = − 0.55, 95% CI: − 0.88 to − 0.23, P = 0.0009), or spring (β = − 0.39, 95% CI: − 0.71 to − 0.07, P = 0.02) had significantly lower endoxifen concentrations compared with samples collected in the winter (Fig. 3) . No evidence of an association was found with other clinical variables: age, race, menopausal status, or concomitant administration of weak CYP2D6 inhibitors (Table 3) .
Adjusted associations for genetic variables
After adjustment for clinical variables with significant univariate associations (CYP2D6 diplotype, weight, and season), the association for CYP2C9 maintained significance (P = 0.02), whereas the association for CYP2C8 was no longer significant (P = 0.11). Interestingly, the association for CYP2C19 was almost significant after adjustment (P = 0.07), whereas the trend for SLCO1B1 disappeared (P = 0.18, Table 2 ).
The trends observed with CYP2C8, CYP2C9, and CYP2C19 are likely because of known linkage disequilibrium between the high-activity CYP2C19*17 and the wild-type CYP2C8 and CYP2C9 (D′ > 0.9) [26] . Therefore, we constructed multivariable models including different combinations of the three genes adjusted for CYP2D6, weight, and season (Supplementary Table 3 , Supplemental digital content, http://links.lww.com/FPC/ B270). Comparing the goodness-of-fit statistics (AIC), the optimal model included only CYP2C9 (P = 0.002, AIC 728.2378, Supplementary Table 3 , Supplemental digital content, http://links.lww.com/FPC/B270). CYP2C9 maintained significance when included in a model with CYP2C19 (P = 0.045) and was borderline significant in a model with CYP2C19 and CYP2C8 (P = 0.07), but neither of these other genes maintained significance when included in a model with CYP2C9 (all P > 0.05), suggesting that CYP2C9 drives the identified associations for all three genes. In the final multivariable model, the addition of the CYP2D6 diplotype explained 15.3% of the variability in steady-state endoxifen concentrations, whereas CYP2C9 (1.3%), weight (5.3%), and season (3.8%) explained relatively little of the residual variability (Table 4) . Table 4 , Supplemental digital content, http://links.lww.com/FPC/ B270) and summer (β = − 0.13, 95% CI: − 0.26 to − 0.0038, P = 0.049) and N-desmethyltamoxifen concentrations were lower in the fall (β = − 1.053, 95% CI: − 1.99 to − 0.12, P = 0.031) compared with winter, similar to the associations detected for endoxifen. Screening predicted activity phenotype, higher SULT1A1 activity was nominally associated with greater endoxifen/4-OH tamoxifen ratio (β = 0.54, 95% CI: 0.04-1.04, P = 0.03), and increased CYP2C8 activity was associated with a higher ratio of endoxifen to N-desmethyltamoxifen (β = 0.01, 95% CI: 0.00-0.02, P = 0.04, Supplementary Table 5 , Supplemental digital content, http://links.lww.com/FPC/B270). Copyright r 2017 Wolters Kluwer Health, Inc. All rights reserved.
Discussion
The effect of genetic variability in CYPs and transporters, aside from CYP2D6, and clinical variables on steady-state endoxifen concentrations has not been explored thoroughly. CYP2D6 is believed to account for around 50% of the metabolism of tamoxifen into endoxifen [7] , leaving a large proportion of the metabolism unexplained. In this study, dozens of functionally relevant SNPs were genotyped to predict a patient's phenotypic activity of nineteen CYPs and transporters to determine whether this activity was associated with variability in endoxifen concentrations. Our findings further support previous analyses suggesting that genetic variation in CYP2C9, weight, and the season of sample collection contribute toward this residual variability. Although there were intriguing trends for CYP2C8 and CYP2C19, multivariable models suggest that these may be spurious associations caused by linkage disequilibrium with CYP2C9.
Our findings support previous work indicating a contribution of CYP2C9 toward endoxifen production. Human liver microsomes homozygous for low-activity CYP2C9 genotypes have lower rates of 4-OH tamoxifen formation than wild-type microsomes [18] . This in-vitro finding has been confirmed in clinical cohorts of tamoxifen-treated patients. Lower steady-state endoxifen [5] or 4-OH tamoxifen [4] concentrations have been detected in patients carrying common, low-activity CYP2C9 polymorphisms (CYP2C9*2 and *3). Recently, Powers et al. [17] utilized a more comprehensive CYP2C9 activity phenotyping approach by integrating uncommon low-activity variants (i.e. *4 and *11) and concomitant inhibitor treatment (i.e. fluoxetine and omeprazole), confirming that patients with decreased CYP2C9 activity have lower endoxifen concentrations. Our results are in line with these previous findings, although we did not have information on CYP2C9 inhibitor coadministration.
Other studies that did not detect associations between Gray boxes denote phenotype groups that did not exist for that gene (See Supplementary Table 2 ). a Bolded P < 0.05. values were adjusted for season, weight, and the CYP2D6 diplotype.
the CYP2C9 phenotype and concentrations of endoxifen or upstream metabolites were likely underpowered because of the rarity of low-activity CYP2C9 variants in patients of Asian descent [7, 8] . Other clinical analyses have reported associations between common functionally consequential polymorphisms in CYP2C19 (i.e. lowactivity *2 and *3 and high-activity *17) and concentrations of tamoxifen and its metabolites [8, 9] . Our multivariable model suggests that CYP2C19 itself makes a negligible, if any, contribution toward endoxifen concentration and these associations can likely be attributable to linkage disequilibrium between the high-activity CYP2C19*17 and the wild-type CYP2C8 and CYP2C9 [26] .
This study, similar to other reports examining BMI, found that higher body weight was associated with lower endoxifen [3, 4] . Body weight was utilized instead of BMI because height information was unavailable. We also detected a significant association with season of sample collection, in which samples collected during the winter had higher concentrations of endoxifen than those collected in other seasons. Slightly higher concentrations of tamoxifen metabolites, but not tamoxifen itself, were also Endoxifen concentration by CYP2C8, CYP2C9, and CYP2C19 activity. Box and whisker plot (circles represent outliers) of steady-state endoxifen concentrations stratified by predicted activity phenotype for CYP2C8 (a), CYP2C9 (b), and CYP2C19 (c). Endoxifen concentration increased as predicted phenotypic activity increased for each gene (P = 0.02, 0.04, and 0.11, respectively).
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identified in the winter, suggesting that this may be a metabolic phenomenon. Previously, two groups have reported the opposite effect, with samples collected in the spring and summer having greater endoxifen concentration than those collected in the winter [10, 27] . The mechanism for this seasonal effect is unclear as the original hypothesis, that seasonal sun-associated vitamin D-induced CYP3A4 activity, was not confirmed by analyses of vitamin D and CYP3A activity in these publications [27] . The reason for the discrepancy in the direction of effect between our study and these previous publications is also not clear, but may be related to geographical differences in sun exposure as our study was carried out in North Carolina, USA. Also, differences in the prevalence of vitamin D supplementation between cohorts could have contributed; however, we did not collect this information. One final possible explanation is increased tamoxifen adherence during winter months because of increased tolerability of hot flashes. In contrast to this hypothesis, tamoxifen concentrations were not different between the seasons. Finally, we did not detect an association with CYP2D6 inhibitor coadministration, which is known to be a major determinant of endoxifen concentration [10, 28] . This is unsurprising as patients taking strong or moderate CYP2D6 inhibitors were excluded from this study and relatively few patients (n =23) were taking weak inhibitors, which likely had a marginal effect on enzyme activity.
Several limitations of this analysis should be considered. The primary limitation is the lack of confirmation from prospective clinical trials that endoxifen serum concentration is associated with tamoxifen treatment efficacy, or perhaps toxicity, in breast cancer patients [29, 30] . In addition, despite our attempt to perform a comprehensive assessment of the known, functionally consequential polymorphisms within genes putatively related to endoxifen concentration, it is likely that our panel did not include some relevant genes and some variants within the genes analyzed, particularly less common variants that have not yet been discovered. The panel utilized was as comprehensive as possible considering the current knowledge in the field. The predicted functionality for polymorphisms was extrapolated from known data, but could have been categorized incorrectly. Further research efforts are needed, likely in well-controlled in-vitro experiments, to estimate the metabolic activity of individual alleles, perhaps accounting for substrate-dependent effects.
Our analysis explained approximately a quarter of the variability in endoxifen concentration, which is lower than reported previously for the CYP2D6 genotype [7] . One possible explanation could be that our samples were collected irrespective of the timing of the last dose. In addition, endoxifen concentration was measured at baseline, assuming that patients were adherent to tamoxifen treatment, as self-reported. Tamoxifen adherence is the highest within the first year of therapy, around 77-88%, and decreases over time [31] ; our patient cohort was taking tamoxifen on average 0.8 years before study entry, suggesting that adherence was relatively high. Finally, we did not perform correction for multiple comparisons, increasing the possibility of false-positive findings; however, the agreement of our findings with previous literature somewhat alleviates this concern.
Conclusion
In this retrospective secondary analysis of data collected from a prospectively enrolled cohort, genetic variation that confers decreased CYP2C9 activity was associated with decreased steady-state endoxifen concentrations. In adjusted analyses, CYP2C9 activity seemed to be independently contributory, whereas CYP2C8 and CYP2C19 were not associated with endoxifen concentration, likely because of known linkage disequilibrium. These results suggest that individualized treatment approaches should consider several genetic and clinical factors in addition to CYP2D6 status to improve treatment efficacy. Further research is needed to integrate these genetic variables into Bold values statistically significant (P < 0.05). an endoxifen prediction algorithm to guide personalized tamoxifen dosing. A combined analysis of existing datasets could be carried out to develop a more comprehensive and accurate algorithm. However, for these algorithms to be clinically useful, endoxifen concentration needs to be associated definitively with tamoxifen treatment outcomes, ideally therapeutic efficacy.
